PP2A-B56-α Antibody (F-4): sc-271311

PP2A-B56-α Antibody (F-4) is a mouse monoclonal IgG1 antibody that detects PP2A-B56-α in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). PP2A-B56-α is a crucial regulatory subunit of the protein phosphatase 2A (PP2A) complex, which plays a significant role in various cellular processes, including cell growth, division, and apoptosis. PP2A-B56-α (F-4) antibody helps researchers study PP2A-B56-α′s ability to modulate PP2A holoenzyme activity, which is essential for maintaining cellular homeostasis and regulating signal transduction pathways. PP2A-B56-α interacts with various catalytic subunits and regulatory proteins, allowing fine-tuning of phosphatase activity in response to cellular signals. Dynamic interaction of PP2A-B56-α with binding partners is vital for proper PP2A complex functioning, and dysregulation has been implicated in various diseases, including cancer. Anti-PP2A-B56-α antibody (F-4) enables researchers to gain insights into PP2A-B56-α′s role in cellular signaling and potential as a therapeutic target.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

PP2A-B56-α Antibody (F-4) References:

1. JNK activation decreases PP2A regulatory subunit B56alpha expression and mRNA stability and increases AUF1 expression in cardiomyocytes.  |  Glaser, ND., et al. 2006. Am J Physiol Heart Circ Physiol. 291: H1183-92. PMID: 16603688
2. Molecular basis for PP2A regulatory subunit B56alpha targeting in cardiomyocytes.  |  Bhasin, N., et al. 2007. Am J Physiol Heart Circ Physiol. 293: H109-19. PMID: 17416611
3. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins.  |  Arnold, HK. and Sears, RC. 2008. Cancer Metastasis Rev. 27: 147-58. PMID: 18246411
4. miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2.  |  Terentyev, D., et al. 2009. Circ Res. 104: 514-21. PMID: 19131648
5. PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells.  |  Mannava, S., et al. 2012. Oncogene. 31: 1484-92. PMID: 21822300
6. The tumor suppressor phosphatase PP2A-B56α regulates stemness and promotes the initiation of malignancies in a novel murine model.  |  Janghorban, M., et al. 2017. PLoS One. 12: e0188910. PMID: 29190822
7. Polycystin-1 Inhibits Cell Proliferation through Phosphatase PP2A/B56α.  |  Tang, Y., et al. 2019. Biomed Res Int. 2019: 2582401. PMID: 31641668
8. Activation of PKC results in improved contractile effects and Ca2+ cycling by inhibition of PP2A-B56α.  |  Pluteanu, F., et al. 2022. Am J Physiol Heart Circ Physiol. 322: H427-H441. PMID: 35119335
9. Impaired myocellular Ca2+ cycling in protein phosphatase PP2A-B56α KO mice is normalized by β-adrenergic stimulation.  |  Glaser, D., et al. 2022. J Biol Chem. 298: 102362. PMID: 35963431
10. KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development.  |  Tinsley, SL., et al. 2024. Oncogene. 43: 3673-3687. PMID: 39443726

The preferred PP2A-B56-α antibody is PP2A-B56-α Antibody (F-10): sc-271151.